| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802723201027 | 272320102 | DEPOLAN F.C.TAB 1MG/TAB BTx20(BLISTERS 2x10) [PVC/PE/PVDC/ ALUMINIUM FOIL) [PVC/PE/PVDC/ ALUMINIUM FOIL) | 1.76 | 1.85 | 2.55 |
| 05/2018 | 2802723201041 | 272320104 | DEPOLAN F.C.TAB 1MG/TAB BTx60(BLISTERS 6x10) [PVC/PE/PVDC/ ALUMINIUM FOIL) [PVC/PE/PVDC/ ALUMINIUM FOIL) | 4.91 | 5.15 | 7.10 |
| 05/2018 | 2802723202017 | 272320201 | DEPOLAN F.C.TAB 2MG/TAB BTx20(BLISTERS 2x10) (PVC/PE/PVDC/ ALUMINIUM FOIL) (PVC/PE/PVDC/ ALUMINIUM FOIL) | 3.79 | 3.98 | 5.48 |
| 05/2018 | 2802723202031 | 272320203 | DEPOLAN F.C.TAB 2MG/TAB BTx60(BLISTERS 6x10) (PVC/PE/PVDC/ ALUMINIUM FOIL) (PVC/PE/PVDC/ ALUMINIUM FOIL) | 10.03 | 10.52 | 14.50 |
| 05/2018 | 2802723203014 | 272320301 | DEPOLAN F.C.TAB 3MG/TAB BTx20(BLISTERS 2x10) [PVC/PE/PVDC/ ALUMINIUM FOIL] [PVC/PE/PVDC/ ALUMINIUM FOIL] | 4.17 | 4.37 | 06.02 |
| 05/2018 | 2802723203038 | 272320303 | DEPOLAN F.C.TAB 3MG/TAB BTx60(BLISTERS 6x10) [PVC/PE/PVDC/ ALUMINIUM FOIL] [PVC/PE/PVDC/ ALUMINIUM FOIL] | 10.99 | 11.53 | 15.89 |
| 05/2018 | 2802723204028 | 272320402 | DEPOLAN F.C.TAB 4MG/TAB BTx20(BLISTERS 2x10) [PVC/PE/PVDC/ ALUMINIUM FOIL] [PVC/PE/PVDC/ ALUMINIUM FOIL] | 7.17 | 7.52 | 10.37 |
| 05/2018 | 2802723204042 | 272320404 | DEPOLAN F.C.TAB 4MG/TAB BTx60(BLISTERS 6x10) [PVC/PE/PVDC/ ALUMINIUM FOIL] [PVC/PE/PVDC/ ALUMINIUM FOIL] | 18.92 | 19.85 | 27.36 |
| 05/2018 | 2802723205018 | 272320501 | DEPOLAN F.C.TAB 6MG/TAB BTx20(BLISTERS 2x10) [PVC/PE/PVDC/ ALUMINIUM FOIL] [PVC/PE/PVDC/ ALUMINIUM FOIL] | 10.10 | 10.59 | 14.60 |
| 05/2018 | 2802723205049 | 272320504 | DEPOLAN F.C.TAB 6MG/TAB BTx60(BLISTERS 6x10) [PVC/PE/PVDC/ ALUMINIUM FOIL] [PVC/PE/PVDC/ ALUMINIUM FOIL] | 26.65 | 27.96 | 38.53 |
For the treatment of schizophrenia in adults and in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17. May also be used to manage symptoms of inappropriate behavior due to aggression and/or psychosis in patients with severe dementia.
Blockade of dopaminergic D2 receptors in the limbic system alleviates positive symptoms of schizophrenia such as hallucinations, delusions, and erratic behavior and speech. Blockade of serotonergic 5-HT<sub>2</sub> receptors in the mesocortical tract, causes an excess of dopamine and an increase in dopamine transmission, resulting in an increase in dopamine transmission and an elimination of core negative symptoms. Dopamine receptors in the nigrostriatal pathway are not affected by risperidone and extrapyramidal effects are avoided. Like other 5-HT<sub>2</sub> antagonists, risperidone also binds at alpha(1)-adrenergic receptors and, to a lesser extent, at histamine H1 and alpha(2)-adrenergic receptors.
Symptoms of overdose include drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms. LD<sub>50</sub>=82.1mg/kg (orally in mice).
Well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.
20-24 hours
Risperidone is extensively metabolized in the liver.In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects.
* 1 to 2 L/kg